Idorsia (OTCMKTS:IDRSF) Shares Down 5.4% – Here’s Why

by · The Cerbat Gem

Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report)’s share price dropped 5.4% during mid-day trading on Thursday. The stock traded as low as $5.30 and last traded at $5.30. 200 shares changed hands during trading, a decline of 98% from the average session volume of 9,700 shares. The stock had previously closed at $5.60.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IDRSF shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating on shares of Idorsia in a research note on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

View Our Latest Report on Idorsia

Idorsia Price Performance

The company’s 50 day simple moving average is $7.00 and its 200 day simple moving average is $5.96.

Idorsia Company Profile

(Get Free Report)

Idorsia Ltd. is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Idorsia retaining Actelion’s research and development operations and a portfolio of pharmaceutical assets.

Idorsia discovers and develops medicines for conditions with significant unmet medical needs, focusing primarily on cardiovascular disease, central nervous system disorders, immunology and rare diseases.

Further Reading